Researchers determine how a protein contributes to human immune defense against RNA viruses
An international research team led by Prof. Dr. Janosch Hennig from the University of Bayreuth has discovered how the TRIM25 ...
Nurix: An Attractive Early-Stage Biotech Play
Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...
Developing a simple, cost-effective method to identify the targets of a crucial protein-modifying enzyme
During ubiquitination, a group of enzymes called E3 ubiquitin ligases attach a small protein called ubiquitin to other ...
technologynetworks9mon
Expanding the PROTACtable Genome Universe of E3 Ligases
However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the vast array of E3 ligases in the human genome have been explored in the TPD field. Dr.
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Kymera Therapeutics is a biotech company with innovative technology targeting disease-causing proteins, offering promising ...
生物通11h
Cell：裂谷热病毒重塑宿主泛素连接酶促进病毒感染致病的新机制
裂谷热病毒（Rift Valley fever virus, ...
Nurix Therapeutics Announces Presentations at Discovery on Target Conference
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...